Companies / Singapore
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Double Milestone For Biomedical Sector
March 2007 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
BMI has reaffirmed its encouraging prospects for Singapore's biomedical sector after UK-based GlaxoSmithKline (GSK) announced that a clinical candidate will emerge from the Biopolis cluster this year and the news that Healtheuniverse - a US regenerative medicines firm - is setting up a subsidiary in the country. Singapore is actively promoting its status as regional hub for the biomedical sciences and milestones like these demonstrate that the country is making headway to achieving that goal. We expect similar developments throughout 2007 and over the next few years. Inevitably, a major new medicine or a revolutionary technology will emerge from research